All Trials

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with ES-SCLC after exactly one prior platinum regimen (± prior PD-(L)1), ECOG 0–1, and measurable disease are randomized to sacituzumab govitecan—an anti–Trop-2 antibody–drug conjugate delivering SN-38—vs investigator’s choice SOC (topotecan, or in Japan topotecan or amrubicin). Excludes prior topoisomerase I–targeting agents and active untreated CNS disease; treated/stable brain mets allowed.

ClinicalTrials.gov ID: NCT06801834

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic or unresectable rare non‑prostate GU cancers (high‑grade neuroendocrine, primary adenocarcinoma [urachal/non‑urachal], squamous cell of bladder/urinary tract, renal medullary carcinoma, or penile SCC) receive sacituzumab govitecan, with addition of atezolizumab for checkpoint inhibitor–naive patients. Sacituzumab govitecan is a Trop‑2–targeted antibody–drug conjugate delivering SN‑38 (topoisomerase I inhibitor), and atezolizumab is a PD‑L1 inhibitor.

ClinicalTrials.gov ID: NCT06161532

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with PD‑1/PD‑L1–refractory extensive-stage SCLC after exactly one prior platinum+PD‑1/L1 regimen are enrolled to receive investigational immunotherapy or ADC regimens, as monotherapy or combined with pembrolizumab. Arms include pembrolizumab+quavonlimab (anti–CTLA‑4), pembrolizumab+quavonlimab+lenvatinib (VEGFR/FGFR TKI), pembrolizumab+MK‑4830 (anti‑ILT4), favezelimab (anti‑LAG‑3)+pembrolizumab, and raludotatug deruxtecan (CDH6‑targeted topoisomerase I ADC).

ClinicalTrials.gov ID: NCT04938817

A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic small cell carcinoma of the bladder or other high‑grade neuroendocrine tumors of the urinary tract (including mixed histology), with measurable progressive disease after, ineligible for, or refusing platinum/etoposide (ECOG 0–2), receive lurbinectedin IV q21d; ICI‑naive, ICI‑eligible patients may also receive avelumab. Lurbinectedin is a selective transcription inhibitor; avelumab is a PD‑L1–blocking antibody.

ClinicalTrials.gov ID: NCT06228066

IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with treatment-naïve extensive-stage small cell lung cancer and radiographic liver metastases receive carboplatin/etoposide plus atezolizumab (anti–PD-L1) and bevacizumab (anti–VEGF) for 4 cycles, followed by maintenance atezolizumab/bevacizumab. Includes ECOG 0–2, measurable disease, and allows selected stable/asymptomatic brain metastases; excludes significant bleeding/thromboembolic risk, uncontrolled hypertension, recent major surgery, active autoimmune disease requiring therapy, and active HBV.

ClinicalTrials.gov ID: NCT05588388

A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated, locally advanced/inoperable or metastatic TNBC (PD‑L1–ineligible or contraindicated for anti–PD-(L)1) or ER-low, HER2‑negative breast cancer ineligible for endocrine therapy, with measurable disease, are randomized to izalontamab brengitecan (BMS‑986507)—a bispecific EGFR/HER3-targeted antibody‑drug conjugate delivering a topoisomerase I inhibitor—versus physician’s choice of paclitaxel, nab‑paclitaxel, capecitabine, or carboplatin/gemcitabine. Key efficacy is assessed by blinded central review, with PFS primary and OS/ORR secondary.

ClinicalTrials.gov ID: NCT06926868

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced EGFR-driven solid tumors, with expansion in squamous histologies (cSCC post/PD-1-ineligible, first-line R/M HNSCC by CPS strata, ICI-naïve SCAC after 1–2 lines, and stage IV squamous NSCLC post 1 line), receive BCA101 (ficerafusp alfa) alone or with pembrolizumab. BCA101 is a bifunctional anti-EGFR/TGF-β “trap” antibody designed to inhibit EGFR and locally neutralize TGF-β1/3; requires measurable disease and mandatory biopsies, excludes prior anti–TGF-β and certain recent anti-EGFR exposure.

ClinicalTrials.gov ID: NCT04429542

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic or unresectable gastrointestinal cancers (including mCRC, gastric/GEJ, pancreatic, cholangiocarcinoma) eligible for FOLFOX, generally after at least one prior line; current randomized expansion focuses on second-line mCRC that is oxaliplatin-naïve, BRAF WT, MSI-stable, and not receiving biologics. Investigational agent BOLD-100, a ruthenium-based compound that inhibits GRP78/BiP to disrupt ER stress and induce apoptosis, is combined with standard FOLFOX.

ClinicalTrials.gov ID: NCT04421820

A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic colorectal adenocarcinoma who progressed after first-line FOLFOX plus bevacizumab (ECOG 0–2), excluding MSI‑H and BRAF V600–mutant tumors, receive fruquintinib (oral VEGFR‑1/2/3 inhibitor) added to standard FOLFIRI as second-line therapy. Single-arm design; treatment continues until progression or intolerance.

ClinicalTrials.gov ID: NCT07011576

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults and children (ECOG 0–3) with newly diagnosed oligometastatic lung, colorectal, or prostate cancer (1–10 lesions; brain mets excluded) are randomized to immediate stereotactic ablative radiotherapy (SABR) to all treatable sites plus standard systemic therapy versus initial standard therapy with SABR delayed ~6 months; a separate cohort allows immediate SABR for broader oligometastatic/oligoprogressive disease. Compares survival/ADT-free survival and safety/quality of life while standard systemic regimens are given per tumor type.

ClinicalTrials.gov ID: NCT06563388